DSMB okays CLPA's Aptosyn Phase III

Cell Pathways (CLPA ) said an independent data and safety monitoring board (DSMB) recommended resuming enrollment in a U.S. double-blind, placebo-controlled Phase III trial of CLPA's Aptosyn exisulind...